Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Ticker: Wegovy and Zepbound prices fall; ExxonMobil and partner Qatar Energy find new natural gas deposit off Cyprus ...

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

Now the shortages of Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound are over. The FDA determined in December and February, respectively, that the companies could meet demand.

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! Ever since blockbuster weight-loss drugs like Wegovy and Zepbound went mainstream, ...

Hims teamed up with Novo Nordisk A/S in April to offer its rival drug Wegovy at a discounted price to patients who use its platform. The telehealth company — and its investors — had been ...

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

People taking Zepbound lost more body weight. Those on Zepbound lost 20.2% of their body weight (about 50 pounds on average), while participants on Wegovy lost 13.7% (about 33 pounds).